Grupo de Cáncer Endocrino Hereditario

Inicio | Investigación e innovación | Programas Científicos | Programa de Genética del Cáncer Humano | Grupo de Cáncer Endocrino Hereditario

“Este contenido se encuentra unicamente en inglés”

Mercedes Robledo
Mercedes Robledo Jefe de Grupo
T +34 917328000 (Ext 3320)
mrobledo@cnio.es

Investigadores

  • Alberto Cascón
  • Cristina Rodríguez

Becarios Post-doctorales

  • Luís Javier Leandro
  • Ángel Mario Martínez
  • Cristina Montero

Becarios Pre-Doctorales

  • Bruna Calsina
  • María Monteagudo
  • Juan María Roldán
  • María Santos

Técnicos de Laboratorio

  • Javier Lanillos
  • Rocío Letón

Our Group is mainly interested in identifying genetic risk factors involved in endocrine tumour susceptibility. Through a comprehensive analysis of tumour genomic features we have been able to propose diagnostic and prognostic markers to identify altered pathways that could be therapeutically targeted, and to identify new major susceptibility genes.

We are also interested in defining markers associated with differences in anticancer drug response and toxicity. We are applying targeted and whole-exome next-generation sequencing to a large series of clinically well-characterised patients. The aim is to identify new therapeutic approaches to personalise cancer treatment. These efforts will collectively improve the diagnosis, prognosis and treatment of patients.

Publicaciones

Subir